thyssenkrupp nucera continues development of green hydrogen

In the green hydrogen (gH2) segment with alkaline water electrolysis (AWE) technology, sales of €103 million (€134 million in 2024) and in the chlor-alkali (CA) segment of €81 million (same €103 million in 2024).

Based on preliminary, unaudited figures, the electrolysis specialist expects consolidated earnings before interest and taxes (EBIT) of €0 million for the 3Q25 (€2 million in 2024). EBIT in the gH2 segment is expected to have risen to -€13 million (prior-year quarter: -€23 million). EBIT in the CA segment amounted to €13 million (€25 million in 2024). In the same period in 2024, one-time effects had caused EBIT in the chlor-alkali segment to rise sharply.

In the first nine months of 2024/25, thyssenkrupp nucera’s consolidated sales increased to €663 million (€609 million in 2024), with the gH2 segment expected to contribute €377 million (€350 million in 2024) and the CA segment €286 million (prior-year period: €259 million).

Consolidated EBIT improved in the first nine months of the current fiscal year 2024/2025 to an estimated €4 million (-€13 million in 2024). EBIT in the gH2 segment was -€39 million (-€61 million in 2024) and €43 million (€47 million in 2024) in the CA segment.

Order intake in the 3Q25 amounted to €63 million (€271 million in 2024). Of this, €13 million was attributable to the gH2 segment (€220 million in 2024) and €50 million to the CA segment (€51 million in 2024). In the same period in 2024, around €200 million related to the Stegra project in Sweden was recorded in order intake in the green hydrogen segment. The total order backlog at group level amounted to around €0.7 billion as of 30 June 2025.

Against the backdrop of a continuing challenging market environment for green hydrogen with ongoing reluctance to make final investment decisions (FID), the management of thyssenkrupp nucera has adjusted its revenue and EBIT outlook for the full year 2024/2025. The company has also specified its EBIT outlook for the two segments gH2 and CA.

“By specifying our revenue and EBIT outlook for our two segments green hydrogen (gH2) and chlor-alkali (CA), we are further increasing our transparency. The upward revision of our EBIT guidance underscores our stable operational performance,” said Dr Stefan Hahn, CFO of thyssenkrupp nucera.

The company now expects consolidated sales for the current 2024/2025 fiscal year to be between €850 million and €920 million; the previous outlook was for consolidated sales of between €850 million and €950 million. In the past fiscal year 2023/2024, consolidated sales of €862 million were achieved.

In the gH2 segment, the company now expects sales for the full year 2024/2025 to be between €450 million and €510 million, compared with the previous outlook of €450 million and €550 million. In the 2023/2024 fiscal year, the electrolysis specialist reported revenue of €524 million in the gH2 business segment.

In the chlor-alkali segment, management continues to expect sales of between €380 million and €420 million for the current 2024/2025 fiscal year. In the 2023/2024 fiscal year just ended, the company generated sales of €338 million in the chlor-alkali segment.

The Management Board has slightly raised its outlook for consolidated EBIT for the 2024/2025 reporting year to between -€7 million and €7 million, after previously expecting EBIT of between -€30 million and €5 million for the 2024/2025 fiscal year. The electrolysis specialist generated consolidated EBIT of -€14 million in the previous reporting year 2023/2024.

For the gH2 segment, the Executive Board now forecasts EBIT of between -€75 million and -€55 million for the current fiscal year 2024/2025; previously, EBIT was expected to improve to a negative mid-double-digit million euro amount. In the previous reporting year 2023/2024, thyssenkrupp nucera achieved EBIT of -€76 million in the gH2 segment. The EBIT outlook for the chlor-alkali segment has been raised. Management now expects EBIT of between €55 million and €75 million, after previously expecting positive EBIT in the mid-double-digit million euro range below the previous year’s figure. The electrolysis specialist achieved EBIT of €62 million in the chlor-alkali electrolysis segment in the past reporting year 2023/2024.

“By adjusting our outlook within or better than the previous guidance, we are providing a more concrete view of our full-year expectations. We expect a more dynamic order intake trend in both the green hydrogen segment and chlor-alkali, and our consistent cost management should enable us to continue generating high-margin growth in the future,” said Dr Werner Ponikwar, CEO of thyssenkrupp nucera.

Read the article online at: https://www.globalhydrogenreview.com/hydrogen/16072025/thyssenkrupp-nucera-continues-development-of-green-hydrogen/